Johnson & Johnson announced the appointment of Ryan Koors to Vice President, Investor Relations, effective May 7, 2026. Koors will report to Johnson & Johnson’s Executive Vice President and Chief Financial Officer, Joseph Wolk. He succeeds Darren Snellgrove who is leaving the company to become the chief financial officer of Halozyme. Koors most recently served as the Chief Financial Officer, Vice President of Finance for Innovative Medicine Global Research & Development
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Underappreciated Autoimmune Franchise Potential Keeps Johnson & Johnson at Buy with Unchanged $275 Price Target
- Johnson & Johnson Shareholders Back Board, Pay at 2026 Meeting
- Johnson & Johnson’s Imaavy granted Priority Review by FDA in hemolytic anemia
- Best ETFs to Invest In, According to AI Analyst, 4/24/2026
- Best ETFs to Invest In, According to AI Analyst, 4/23/2026